Moreover, it renders the possibility of a novel therapeutic target on the signaling of Netrin-1/DCC/GluA1, which could provide substantial benefit to patients with IBS induced by EALs in clinics. This evidence concerns the gene NTN1 and irritable bowel syndrome.